Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01370642 |
Recruitment Status :
Completed
First Posted : June 10, 2011
Results First Posted : October 6, 2014
Last Update Posted : October 18, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hepatitis C, Chronic | Drug: vaniprevir Drug: Placebo to vaniprevir Biological: Peg-IFN Drug: ribavirin | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 294 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Phase III Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of MK-7009 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Japanese Treatment-Naïve Patients With Chronic Hepatitis C Infection |
Actual Study Start Date : | June 27, 2011 |
Actual Primary Completion Date : | July 31, 2013 |
Actual Study Completion Date : | March 17, 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: Vaniprevir 12 Week Arm
Participants on this arm receive 12 weeks of vaniprevir (300 mg twice daily) and then 12 weeks of placebo to vaniprevir along with 24 weeks of treatment with peg-IFN and RBV.
|
Drug: vaniprevir
Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
Other Name: MK-7009 Drug: Placebo to vaniprevir Placebo to vaniprevir, capsules, orally, twice daily for 12 weeks or 24 weeks Biological: Peg-IFN Peg-IFN 1.5 μg/kg once per week, subcutaneously (SC) for 24 or 48 weeks
Other Name: PegIntron Drug: ribavirin Capsules containing 200 mg RBV orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 or 48 weeks
Other Name: REBETOL® |
Experimental: Vaniprevir 24 Week Arm
Participants on this arm receive 24 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV.
|
Drug: vaniprevir
Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
Other Name: MK-7009 Biological: Peg-IFN Peg-IFN 1.5 μg/kg once per week, subcutaneously (SC) for 24 or 48 weeks
Other Name: PegIntron Drug: ribavirin Capsules containing 200 mg RBV orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 or 48 weeks
Other Name: REBETOL® |
Active Comparator: Control Arm
Participants on this arm receive 24 weeks of treatment with placebo to vaniprevir along with 48 weeks of treatment with peg-IFN and RBV.
|
Drug: Placebo to vaniprevir
Placebo to vaniprevir, capsules, orally, twice daily for 12 weeks or 24 weeks Biological: Peg-IFN Peg-IFN 1.5 μg/kg once per week, subcutaneously (SC) for 24 or 48 weeks
Other Name: PegIntron Drug: ribavirin Capsules containing 200 mg RBV orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 or 48 weeks
Other Name: REBETOL® |
- Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Completion of All Study Therapy (SVR24) [ Time Frame: 24 weeks after 24 or 48 weeks of study therapy (up to 72 weeks) ]SVR24 was defined as having an undetectable HCV RNA level 24 weeks after completion of all study therapy.
- Percentage of Participants With One or More Tier 1 Adverse Events (AEs) During the Study [ Time Frame: From Day 1 (post-dose) through completion of Week 24 Follow-up (up to 72 weeks) ]An adverse experience was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the product, was also an adverse experience. For this study, safety parameters or AEs of special interest that were identified a priori constituted "Tier 1" safety endpoints that were subject to inferential testing for statistical significance. Tier 1 AEs on this study included serious rash, anemia (anemia plus haemoglobin decreased), neutropenia (neutropenia plus neutrophil count decreased), bilirubin increased and gastrointestinal adverse (GI) experiences (vomiting, nausea, and diarrhea).
- Percentage of Participants Who Discontinued Study Drug Due to an AE [ Time Frame: From Day 1 (post-dose) through completion of Week 24 Follow-up (up to 72 weeks) ]An adverse experience was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the product, was also an adverse experience.
- Percentage of Participants Achieving SVR12 [ Time Frame: 12 weeks after 24 or 48 weeks of study therapy (up to 60 weeks) ]SVR12 was defined as having an undetectable HCV RNA level 12 weeks after completion of all study therapy.
- Percentage of Participants Achieving Rapid Virologic Response (RVR) [ Time Frame: At Week 4 ]RVR was defined as having an undetectable HCV RNA level at Week 4.
- Percentage of Participants Achieving Complete Early Virologic Response (cEVR) [ Time Frame: At Week 12 ]cEVR was defined as having an undetectable HCV RNA level at Week 12.
- Percentage of Participants Achieving Undetectable HCV RNA at the End of Treatment (EOT) [ Time Frame: At Week 24 or 48 ]Participants were assessed for undetectable HCV RNA levels at the end of all study therapy.
- Least Squares (LS) Mean Change From Baseline in HCV RNA (Log 10) [ Time Frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 24 ]HCV RNA levels were assessed at baseline (BL) and during treatment weeks 2, 4, 8, 12, and 24 using the Roche TaqMan HCV assay, and transformed to Log 10 values. HCV RNA values below the limit of reliable quantification (LoQ) or the limit of detection (LoD) at any time point were handled as follows (imputations done for computational purposes): values below the LoQ but above the LoD were imputed with the LoQ minus 0.1; values below the LoD were imputed with the value of 0 Log IU/mL. HCV RNA levels below the LoD were considered "undetectable".

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
- Japanese participant diagnosed with compensated CHC GT 1
- Absence of ascites, bleeding esophageal varices, hepatic encephalopathy, or other signs or symptoms of advanced liver disease.
- IFN treatment naive
- No evidence of cirrhosis
Exclusion criteria:
- Co-infection with human immunodeficiency virus (HIV)
- Positive hepatitis B surface antigen or other evidence of active hepatitis B infection
- Any other condition that is contraindicated or for which caution is required for treatment with peg-IFN or RBV
- Any condition or pre-study laboratory abnormality, or history of any illness, that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering the study drugs, peg-IFN and RBV, to the participant.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01370642
Study Director: | Medical Director | Merck Sharp & Dohme LLC |

Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Merck Sharp & Dohme LLC |
ClinicalTrials.gov Identifier: | NCT01370642 |
Other Study ID Numbers: |
7009-043 |
First Posted: | June 10, 2011 Key Record Dates |
Results First Posted: | October 6, 2014 |
Last Update Posted: | October 18, 2018 |
Last Verified: | September 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf |
URL: | http://engagezone.msd.com/ds_documentation.php |
Hepatitis A Hepatitis C Hepatitis C, Chronic Hepatitis Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Infections Enterovirus Infections Picornaviridae Infections |
RNA Virus Infections Blood-Borne Infections Communicable Diseases Flaviviridae Infections Hepatitis, Chronic Ribavirin Antimetabolites Molecular Mechanisms of Pharmacological Action Antiviral Agents Anti-Infective Agents |